JP5877731B2 - Ucp−3発現促進剤 - Google Patents
Ucp−3発現促進剤 Download PDFInfo
- Publication number
- JP5877731B2 JP5877731B2 JP2012041478A JP2012041478A JP5877731B2 JP 5877731 B2 JP5877731 B2 JP 5877731B2 JP 2012041478 A JP2012041478 A JP 2012041478A JP 2012041478 A JP2012041478 A JP 2012041478A JP 5877731 B2 JP5877731 B2 JP 5877731B2
- Authority
- JP
- Japan
- Prior art keywords
- ucp
- expression
- epigallocatechin
- expression promoter
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102100040216 Mitochondrial uncoupling protein 3 Human genes 0.000 title claims description 38
- 101710112412 Mitochondrial uncoupling protein 3 Proteins 0.000 title claims description 38
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 claims description 45
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 claims description 24
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 claims description 24
- 239000004480 active ingredient Substances 0.000 claims description 9
- 230000001737 promoting effect Effects 0.000 description 21
- 102000008200 Uncoupling Protein 3 Human genes 0.000 description 12
- 108010021098 Uncoupling Protein 3 Proteins 0.000 description 12
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 208000008589 Obesity Diseases 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 235000020824 obesity Nutrition 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 235000021588 free fatty acids Nutrition 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- 102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 description 4
- 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 206010008118 cerebral infarction Diseases 0.000 description 4
- 238000012937 correction Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- XMOCLSLCDHWDHP-SWLSCSKDSA-N (+)-Epigallocatechin Natural products C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-SWLSCSKDSA-N 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 2
- 230000002407 ATP formation Effects 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 239000012752 auxiliary agent Substances 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940030275 epigallocatechin gallate Drugs 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 230000010627 oxidative phosphorylation Effects 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 210000000229 preadipocyte Anatomy 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- WMBWREPUVVBILR-GHTZIAJQSA-N (+)-gallocatechin gallate Chemical compound O([C@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-GHTZIAJQSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000021559 Dicerandra Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 125000002490 anilino group Chemical class [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- LVJJFMLUMNSUFN-UHFFFAOYSA-N gallocatechin gallate Natural products C1=C(O)C=C2OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C1OC(=O)C1=CC(O)=C(O)C(O)=C1 LVJJFMLUMNSUFN-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 150000003585 thioureas Chemical class 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Description
本実施形態のUCP−3発現促進剤は、エピガロカテキンを有効成分として含有するものである。
エピガロカテキン(試料1)、ガロカテキン(試料2)、及びエピガロカテキンガレート(試料3)について、以下のようにしてUCP−3発現促進作用を試験した。
式中Aは「被験試料添加時の補正値」を表し、Bは「試料無添加時の補正値」を表す。
結果を表1に示す。
Claims (1)
- エピガロカテキンを有効成分として含有することを特徴とするUCP−3発現促進剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012041478A JP5877731B2 (ja) | 2012-02-28 | 2012-02-28 | Ucp−3発現促進剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012041478A JP5877731B2 (ja) | 2012-02-28 | 2012-02-28 | Ucp−3発現促進剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013177334A JP2013177334A (ja) | 2013-09-09 |
JP5877731B2 true JP5877731B2 (ja) | 2016-03-08 |
Family
ID=49269405
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012041478A Active JP5877731B2 (ja) | 2012-02-28 | 2012-02-28 | Ucp−3発現促進剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5877731B2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107638569A (zh) * | 2016-07-21 | 2018-01-30 | 上海聿健生物科技有限公司 | 增强褐色脂肪细胞产热效率的方法和应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005027661A1 (en) * | 2003-09-23 | 2005-03-31 | Dsm Ip Assets B.V. | Compositions for the treatment and prevention of diabetes mellitus |
-
2012
- 2012-02-28 JP JP2012041478A patent/JP5877731B2/ja active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107638569A (zh) * | 2016-07-21 | 2018-01-30 | 上海聿健生物科技有限公司 | 增强褐色脂肪细胞产热效率的方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
JP2013177334A (ja) | 2013-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5389434B2 (ja) | アディポネクチン発現低下抑制剤及びその用途 | |
WO2016063901A1 (ja) | 環状ジペプチドを有効成分とする皮膚保湿機能改善剤 | |
CN101827576B (zh) | 潘多汀衍生物或包含所述潘多汀衍生物的蓬莪萃取物的新用途 | |
KR101842948B1 (ko) | 데칸알 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 근육 질환 예방 또는 치료용 조성물 | |
US20210213085A1 (en) | Pharmaceutical Composition for Preventing or Treating Muscle Diseases, Containing Ginseng Berry Extract as Active Ingredient | |
JP5877731B2 (ja) | Ucp−3発現促進剤 | |
JP7282335B2 (ja) | グアニジン誘導体を含む発毛促進用組成物 | |
JP5819209B2 (ja) | 幹細胞から褐色脂肪細胞への分化促進剤 | |
JP2020040884A (ja) | アーティチョーク葉抽出物又はシナロピクリンを含む、筋肉細胞におけるエネルギー代謝の活性化による抗疲労用組成物 | |
JP6034107B2 (ja) | 幹細胞から褐色脂肪細胞への分化促進剤 | |
CN115315197A (zh) | 细胞衰老抑制用组合物及抑制细胞衰老的方法 | |
CN112007039B (zh) | 一种包含氟西汀和维生素d3或其衍生物的组合物,及其应用 | |
JP6441364B2 (ja) | ジベンゾ−アルファ−ピロンを用いた体重増加制御 | |
JP2018140947A (ja) | コラーゲン産生の促進を特徴とする組成物およびリモノイド | |
CN115867289A (zh) | 含有nr及/或nmn与芝麻素类的组合物 | |
JP2017048155A (ja) | Dkk1発現促進剤および美白剤 | |
JP6002510B2 (ja) | エストロゲン受容体β活性化剤 | |
JP2018108973A (ja) | Xvii型コラーゲン産生促進剤 | |
JP7315940B2 (ja) | 線維芽細胞増殖因子-5発現抑制剤 | |
JP7455350B2 (ja) | 大気汚染物質によるダメージ抑制剤、化粧料及び飲食品 | |
JP2011026240A (ja) | 花粉荷を含有する育毛剤 | |
JP7402478B2 (ja) | 神経成長因子発現抑制剤およびセマフォリン3a発現促進剤 | |
JP2021050178A (ja) | 糖化に起因した保湿機能低下の抑制剤、皮膚化粧料および飲食品 | |
TW202222329A (zh) | 增加肌肉量、增加肌力、抑制肌肉量減少或抑制肌力下降用組成物 | |
JP2012056905A (ja) | 筋肉タンパク質分解抑制剤としてのジブトキシブタン |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20141126 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20151016 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151020 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160119 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160126 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5877731 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |